Melanie A. Felmlee, Robert S. Jones, Vivian Rodriguez-Cruz, Kristin E. Follman, Marilyn E. Morris
9 min
The solute carrier family 16 (SLC16) consists of 14 monocarboxylate transporter (MCT) isoforms that facilitate the proton-dependent transport of essential nutrients, including L-lactate, pyruvate, ketone bodies, and short-chain fatty acids. These transporters are fundamental to maintaining intracellular pH and metabolic homeostasis across various tissues. While MCT1-4 have been extensively studied due to their ubiquitous expression and critical role in glycolytic metabolism, the remaining isoforms (MCT5-14) are less characterized, though recent research has begun to uncover their specific roles in hormone transport, drug disposition, and disease pathology.
MCTs are increasingly recognized as key players in human disease. In oncology, the Warburg effect—where cancer cells rely on glycolysis—makes MCT1 and MCT4 essential for exporting excess lactate to prevent intracellular acidification, identifying them as promising therapeutic targets. Beyond cancer, the family is linked to diverse conditions: MCT8 mutations cause Allan-Herndon-Dudley syndrome (an X-linked intellectual disability) due to impaired thyroid hormone transport in the brain, while variants in MCT11 have been identified as risk factors for type 2 diabetes. Furthermore, MCT12 has been implicated in age-related cataracts and renal creatine handling, highlighting the broad clinical significance of this transporter family.
Proper MCT function is highly dependent on ancillary proteins, specifically CD147 (basigin) and embigin, which act as chaperones to facilitate the trafficking of MCTs to the plasma membrane. Without these partners, many MCT isoforms remain sequestered within the cell. Additionally, the activity of MCT1 and MCT4 is significantly enhanced by interactions with intra- and extracellular carbonic anhydrases, which function as a proton-collecting antenna to accelerate transport. Transcriptional regulation is also complex, involving factors such as HIF-1a (for MCT4 under hypoxia) and PPARa, as well as epigenetic mechanisms like DNA methylation, which can silence transporter expression in various cancers.
Sam: Both kinds of evidence appear. In cells engineered to express MCT11, reducing CD147 significantly reduced transporter at the plasma membrane. Researchers also confirmed a direct interaction between the proteins. That's stronger mechanistic evidence than simply finding their expression levels correlated.
Alex: And MCT11 is one of the newer disease-linked members. Does that delivery mechanism help explain the disease association?
Sam: It provides part of the connection. Human variants associated with type two diabetes disrupted membrane trafficking. A diabetes-associated haplotype—a group of inherited variants—also reduced gene expression and cell-surface localization. The review links these changes to altered fatty-acid and lipid metabolism.
Alex: But that's not yet proof that increasing the transporter would treat diabetes.
Sam: The authors present that as a therapeutic possibility. The mechanism remains unresolved, and the review also describes mouse research suggesting abnormal function of a mutant protein. So this is a promising connection with competing mechanistic details still to clarify.
Alex: Let's move to cancer, where the therapeutic argument seems more developed. Why would blocking fuel transport hurt a tumour?
Sam: Highly glycolytic tumour cells rely heavily on breaking down glucose. That produces lactate, and its transport helps maintain intracellular acidity at levels compatible with growth. The established lactate transporters move cargo together with protons—hydrogen ions involved in acidity.
Alex: So these proteins aren't just supplying fuel. They also help cells manage the chemical conditions that let metabolism continue.
Sam: That's central to the review. MCT1 and MCT4 are overexpressed in several cancers, and their expression has been associated with poorer prognosis in particular cancer types. Their role in energy metabolism and acidity makes inhibition a plausible treatment strategy.
Alex: Overexpression alone wouldn't convince me. What happens when transport is actually inhibited?
Sam: The review reports inhibited growth in cancer cell lines. It also describes AZD3965, an inhibitor that reduced tumour growth and increased lactate within tumours in small-cell lung cancer models. Compared with older inhibitors, newer compounds offer greater potency and partial specificity.
Alex: Partial specificity still leaves uncertainty about what's being blocked. How far had that approach reached in patients?
Sam: At the time of this review, AZD3965 was in phase one clinical trials for certain lymphomas. That's the review's reported development stage, not evidence of established clinical benefit. The cancer argument is mechanistically supported, but treatment efficacy is not settled here.
Alex: Regulation could also complicate the target. Do the transporters respond similarly when a tumour has little oxygen?
Sam: They don't share one regulatory programme. Low oxygen increases MCT4 expression through hypoxia-inducible factor, a regulator of the response to oxygen shortage. Other regulators increase MCT1 but not MCT4. That distinction matters when choosing which transporter to investigate.
Alex: And gene regulation isn't the only layer. Does the review give a concrete example of changes beyond the DNA sequence?
Sam: It discusses DNA methylation: chemical marks that can change gene expression. In aorta samples, MCT3 expression decreased as methylation increased. The highest methylation, eighty percent, occurred in samples with severe atherosclerosis, compared with less severe disease.
Alex: That's a striking descriptive number, but it doesn't tell us whether methylation drove the disease or accompanied it.
Sam: The review presents a relationship with disease severity, not proof of that causal direction. The excerpt doesn't provide the sample size for that result. Similar caution applies to several expression and disease associations across the family.
Alex: Where does the review offer a clearer human link between transporter disruption and disease?
Sam: MCT8, which transports thyroid hormones, is a strong example. Mutations cause Allan-Herndon-Dudley syndrome, an inherited disorder involving intellectual disability and impaired muscular activity. The review connects it to disrupted hormone uptake, including limited uptake at the blood-brain barrier.
Alex: That also shows why blood concentrations can mislead. High circulating hormone doesn't necessarily mean enough reaches the cells that need it.
Sam: In this disorder, reduced cellular uptake accompanies elevated circulating thyroid hormone. The review describes both insufficient intracellular hormone and high plasma hormone as contributing to symptoms. Transport location matters, not just total availability.
Alex: With evidence ranging from human mutations to engineered cells, what should listeners trust most?
Sam: I'd trust the established transport functions and mechanisms supported across several experimental approaches most. I'd be more cautious about newer therapeutic proposals. Some members still lack known cargo, and several disease links remain gene associations or preclinical observations.
Alex: So who should read the full review, and where should they begin?
Sam: Cancer-metabolism researchers should start with the Health and Disease discussion of the lactate transporters, then read Regulation. Researchers studying thyroid or metabolic disorders should start with their relevant transporter subsection. For drug-disposition work, begin with Substrates and Inhibitors, then check expression and localization.
Alex: And if someone only needs the broad lesson rather than the complete family map?
Sam: A transporter's abundance doesn't tell you whether it's on the cell surface, what it's moving, or whether blocking it helps. This review is useful because it connects those questions—and shows where the answers are still missing.
Alex: Keep those distinctions in mind when you read the next transporter claim.